Cerus Q3 adjusted EBITDA beats analyst estimates on higher IFC sales, platelet franchise strength

Overview

• Blood safety technology firm's Q3 product revenue rose 10% yr/yr

• Adjusted EBITDA for Q3 beat analyst expectations

• Company announced positive topline results from Phase 3 RedeS trial for INTERCEPT RBC system

Outlook

• Cerus maintains full-year 2026 product revenue guidance of $229 mln to $231 mln

• Company expects 2026 IFC revenue of $23 mln to $25 mln

• Cerus anticipates continued growth in IFC business and international INT 200 rollout

Result Drivers

• IFC SALES - Co said Q3 growth was driven by higher U.S. INTERCEPT Fibrinogen Complex sales

• PLATELET FRANCHISE - Strength in U.S. platelet franchise contributed to revenue growth

• INT200 ROLLOUT - INT200 illuminator sales in EMEA supported quarterly revenue

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Cerus Corp is $5.00, about 119.3% above its October 30 closing price of $2.28

Reuters Recommended Reads

• Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

• Nov 2 - IDEXX raises forecast, betting diagnostics can offset weak vet visits

• Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)